Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function.
about
Higher prevalence of obesity and overweight without an adverse metabolic profile in girls with central precocious puberty compared to girls with early puberty, regardless of GnRH analogue treatmentAromatase inhibitors for short stature in male children and adolescentsAromatase inhibitors for short stature in male children and adolescentsLong-term effects of gonadotropin-releasing hormone analogs in girls with central precocious pubertyChallenges and controversies in diagnosis and management of gonadotropin dependent precocious puberty: An Indian perspectiveResults of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty.Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery.Effect of gonadotropin-releasing hormone agonist therapy on body mass index and growth in girls with idiopathic central precocious puberty.Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal StudyContemporary issues in precocious pubertyModels for predicting the adult height and age at first menstruation of girls with idiopathic central precocious puberty.Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus.Age at menarche and near final height after treatment with gonadotropin-releasing hormone agonist alone or combined with growth hormone in Korean girls with central precocious puberty.Predicting the adult height of girls with central precocious puberty.Efficacy and safety of domestic leuprorelin in girls with idiopathic central precocious puberty: a multicenter, randomized, parallel, controlled trialBody mass index in girls with idiopathic central precocious puberty during and after treatment with GnRH analogues.Serum Anti-Müllerian Hormone Levels in Precocious Puberty Girls according to Stage of GnRH Agonist Treatment.Leptin and adiponectin levels in girls with central precocious puberty before and during GnRH agonist treatment.Current pharmacotherapy of central precocious puberty by GnRH analogs: certainties and uncertainties.Pros and cons of GnRHa treatment for early puberty in girls.A pediatrician's guide to central precocious puberty.Central precocious puberty: revisiting the diagnosis and therapeutic management.Hypothalamic hamartoma with epilepsy: Review of endocrine comorbidity.The influence of gonadotropin releasing hormone agonist treatment on the body weight and body mass index in girls with idiopathic precocious puberty and early pubertyChange in body mass index and insulin resistance after 1-year treatment with gonadotropin-releasing hormone agonists in girls with central precocious puberty.The different effects of gonadotropin-releasing hormone agonist therapy on body mass index and growth between normal-weight and overweight girls with central precocious puberty.Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone agonist with or without growth hormone.Precocious puberty--perspectives on diagnosis and management.Overnight luteinizing and follicle stimulating hormone profiles during GnRHa treatment in short girls born small for gestational age.Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment.GnRH agonist treatment for idiopathic central precocious puberty can improve final adult height in Chinese girls.A Critical Appraisal of the Effect of Gonadotropin-Releasing Hormon Analog Treatment on Adult Height of Girls with Central Precocious Puberty.Effect of gonadotropin-releasing hormone analogue on final adult height among Jordanian children with precocious puberty.Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy.Effect of GnRHa 3.75 mg subcutaneously every 6 weeks on adult height in girls with idiopathic central precocious puberty.Evaluation of central precocious puberty treatment with GnRH analogue at the Triangulo Mineiro Federal University (UFTM).Fractures in spina bifida from childhood to young adulthood.Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty.Growth hormone in combination with leuprorelin in pubertal children with idiopathic short stature.The effect of gonadotrophin-releasing hormone agonist treatment over 3 years on bone mineral density and body composition in girls with central precocious puberty.
P2860
Q21245398-BAAFE3DC-161F-42BC-8799-81C18C778202Q24186574-24E811CC-DF86-449F-A429-CD872924660DQ24202097-0EF786D8-DD76-48C6-985C-464A261CBF53Q26851792-95886013-C878-4F7D-B6F6-3C14836342CCQ28085099-8A342D97-0AAD-4C19-802F-52E053D3094DQ30437688-F9BA0AB6-6509-4A09-9FE4-AE93B89FEDEDQ34711579-2565CD01-4974-4EB6-A5C8-47BE19C5D7E8Q35056370-6C7A4DAB-2F55-4823-9669-BFEB8C617D60Q35173681-D8F93E24-DCCC-4D74-B36D-E47D74D5D0BBQ35244581-3B5A4960-006F-439E-B9E3-CC4D22F87B1BQ35250169-8CD29B31-F15C-4FF5-B2A0-C2DFC2474080Q35554367-984F45B2-6111-4F54-9C56-0260E25BF87FQ36237128-4AD1C2F6-A212-4755-8A49-55E279E1173DQ36516478-20E4B73A-35A3-4AEF-973D-615A95DDD4A3Q36794450-F65FADA9-3BFA-47A5-BD1A-98D1D56F8FB0Q37154131-E9D2BC8E-8EBB-430B-B454-2607A8626EC8Q37622327-6ABAC512-6CCA-41CE-A7A9-84EF63262EC1Q37622451-923F4C2E-A49F-4894-9E0B-93D3FF088851Q38115615-A34299AB-F7AE-4A45-9329-0F6494B5591AQ38202811-428CE8D6-E106-48C3-9823-9778EA2A7142Q38229301-3C2E4404-FAB8-4E0D-84BB-1E33B4E92D2BQ38837184-5B6CDAFE-93F9-4557-90D1-23CF81BAFC72Q39357860-772B72A9-97A1-4A49-9DE2-FC1AFD7A496BQ40970685-5531BADC-D48E-4DBC-AFB5-663F73EFFDCDQ41975684-32BF2AF1-CE15-4E88-8AA2-2591B360048BQ41992890-D8142682-C06C-4A85-8215-F3B85C6690ADQ42096103-D609CDED-727D-4ABA-8983-B78009C4823FQ42444376-956A4E5B-5745-4F28-BF9A-D14632D831CCQ46007732-40C61F68-35AB-47EE-8392-B64102F758E6Q46476454-9F8B0E09-74BA-40C7-90A6-C79A12442167Q47172109-FE6A75AE-2721-44EF-B28D-EAB57AE969EAQ47172921-5E4F58DF-37AE-4561-8DB9-78CB97F7B513Q47177502-297DF463-4941-4FB4-A509-B2FACB23AED0Q47178837-BCF08644-5E3A-4964-863F-5541258EDD1AQ47403632-EA4E5403-3EC9-4DC2-80EC-A231C8973D26Q47997090-B8510BEA-90E7-4EEB-A0EC-DCC3B4E9D85AQ48099519-317FBC91-B18F-4E35-BFC8-BA59FBE88DA1Q51625492-D297BD9A-720E-472F-ACC1-D152D25FA5D5Q52579773-8F7C1A62-75AC-4857-881A-0DC6E4DE6B07Q53379250-FB972178-4CD6-488F-BECB-FC02B67FD1CF
P2860
Long-term observation of 87 girls with idiopathic central precocious puberty treated with gonadotropin-releasing hormone analogs: impact on adult height, body mass index, bone mineral content, and reproductive function.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Long-term observation of 87 gi ...... nt, and reproductive function.
@en
Long-term observation of 87 gi ...... nt, and reproductive function.
@nl
type
label
Long-term observation of 87 gi ...... nt, and reproductive function.
@en
Long-term observation of 87 gi ...... nt, and reproductive function.
@nl
prefLabel
Long-term observation of 87 gi ...... nt, and reproductive function.
@en
Long-term observation of 87 gi ...... nt, and reproductive function.
@nl
P2093
P356
P1476
Long-term observation of 87 gi ...... nt, and reproductive function.
@en
P2093
Anna Maria Pasquino
Fabiana Accardo
Ida Pucarelli
Maria Segni
Raffaella Di Nardo
Vitan Demiraj
P304
P356
10.1210/JC.2007-1216
P407
P577
2007-10-16T00:00:00Z